2.43 USD
-0.02 (-0.82%)
2.43 USD
0 (0%)
Overall STXS gets a fundamental rating of 2 out of 10. We evaluated STXS against 184 industry peers in the Health Care Equipment & Supplies industry. The financial health of STXS is average, but there are quite some concerns on its profitability. STXS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year STXS has reported negative net income.
STXS had a negative operating cash flow in the past year.
In the past 5 years STXS always reported negative net income.
In the past 5 years STXS always reported negative operating cash flow.
1.2 Ratios
STXS has a worse Return On Assets (-59.84%) than 70.65% of its industry peers.
The Return On Equity of STXS (-364.90%) is worse than 79.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -59.84% | ||
| ROE | -364.9% | ||
| ROIC | N/A |
ROA(3y)-47.89%
ROA(5y)-35.58%
ROE(3y)-127.97%
ROE(5y)-86.89%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
STXS's Gross Margin of 50.17% is in line compared to the rest of the industry. STXS outperforms 44.02% of its industry peers.
In the last couple of years the Gross Margin of STXS has declined.
The Profit Margin and Operating Margin are not available for STXS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 50.17% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.5%
GM growth 5Y-7.2%
2. Health
2.1 Basic Checks
STXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for STXS has been increased compared to 1 year ago.
Compared to 5 years ago, STXS has more shares outstanding
There is no outstanding debt for STXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -16.59, we must say that STXS is in the distress zone and has some risk of bankruptcy.
STXS has a worse Altman-Z score (-16.59) than 88.59% of its industry peers.
There is no outstanding debt for STXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.59 |
ROIC/WACCN/A
WACC8.81%
2.3 Liquidity
STXS has a Current Ratio of 1.06. This is a normal value and indicates that STXS is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.06, STXS is not doing good in the industry: 88.59% of the companies in the same industry are doing better.
STXS has a Quick Ratio of 1.06. This is a bad value and indicates that STXS is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.59, STXS is not doing good in the industry: 91.85% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.59 |
3. Growth
3.1 Past
The earnings per share for STXS have decreased by 0.00% in the last year.
The Revenue has been growing slightly by 0.55% in the past year.
The Revenue has been decreasing by -1.41% on average over the past years.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
Revenue 1Y (TTM)0.55%
Revenue growth 3Y-8.4%
Revenue growth 5Y-1.41%
Sales Q2Q%-18.83%
3.2 Future
STXS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.84% yearly.
Based on estimates for the next years, STXS will show a very strong growth in Revenue. The Revenue will grow by 28.33% on average per year.
EPS Next Y13.03%
EPS Next 2Y16.48%
EPS Next 3Y17.84%
EPS Next 5YN/A
Revenue Next Year20.4%
Revenue Next 2Y25.03%
Revenue Next 3Y28.33%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
STXS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year STXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
STXS's earnings are expected to grow with 17.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.48%
EPS Next 3Y17.84%
5. Dividend
5.1 Amount
No dividends for STXS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
2.43
-0.02 (-0.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners46.53%
Inst Owner Change2.78%
Ins Owners19.06%
Ins Owner Change5.06%
Market Cap226.77M
Revenue(TTM)26.92M
Net Income(TTM)-24.64M
Analysts82
Price Target4.28 (76.13%)
Short Float %4.74%
Short Ratio5.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.96%
Min EPS beat(2)5.34%
Max EPS beat(2)24.59%
EPS beat(4)2
Avg EPS beat(4)-13.8%
Min EPS beat(4)-49.39%
Max EPS beat(4)24.59%
EPS beat(8)3
Avg EPS beat(8)-12.25%
EPS beat(12)5
Avg EPS beat(12)-9.56%
EPS beat(16)7
Avg EPS beat(16)-10.57%
Revenue beat(2)2
Avg Revenue beat(2)6.35%
Min Revenue beat(2)6.15%
Max Revenue beat(2)6.54%
Revenue beat(4)3
Avg Revenue beat(4)9.1%
Min Revenue beat(4)-3.27%
Max Revenue beat(4)26.98%
Revenue beat(8)3
Avg Revenue beat(8)-4.79%
Revenue beat(12)4
Avg Revenue beat(12)-4.19%
Revenue beat(16)6
Avg Revenue beat(16)-3.64%
PT rev (1m)-1.18%
PT rev (3m)-6.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-11.22%
EPS NY rev (3m)-8.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-5.17%
Revenue NY rev (3m)-5.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.13 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 33.59 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.19
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0.34
BVpS0.07
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -59.84% | ||
| ROE | -364.9% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 50.17% | ||
| FCFM | N/A |
ROA(3y)-47.89%
ROA(5y)-35.58%
ROE(3y)-127.97%
ROE(5y)-86.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.5%
GM growth 5Y-7.2%
F-Score4
Asset Turnover0.77
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 2.39% | ||
| Cap/Sales | 0.11% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.06 | ||
| Quick Ratio | 0.59 | ||
| Altman-Z | -16.59 |
F-Score4
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)206.17%
Cap/Depr(5y)389.02%
Cap/Sales(3y)3.32%
Cap/Sales(5y)2.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
EPS Next Y13.03%
EPS Next 2Y16.48%
EPS Next 3Y17.84%
EPS Next 5YN/A
Revenue 1Y (TTM)0.55%
Revenue growth 3Y-8.4%
Revenue growth 5Y-1.41%
Sales Q2Q%-18.83%
Revenue Next Year20.4%
Revenue Next 2Y25.03%
Revenue Next 3Y28.33%
Revenue Next 5YN/A
EBIT growth 1Y-12.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.2%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y26.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.75%
OCF growth 3YN/A
OCF growth 5YN/A
STEREOTAXIS INC / STXS FAQ
What is the ChartMill fundamental rating of STEREOTAXIS INC (STXS) stock?
ChartMill assigns a fundamental rating of 2 / 10 to STXS.
What is the valuation status for STXS stock?
ChartMill assigns a valuation rating of 0 / 10 to STEREOTAXIS INC (STXS). This can be considered as Overvalued.
What is the profitability of STXS stock?
STEREOTAXIS INC (STXS) has a profitability rating of 0 / 10.
How financially healthy is STEREOTAXIS INC?
The financial health rating of STEREOTAXIS INC (STXS) is 4 / 10.
What is the expected EPS growth for STEREOTAXIS INC (STXS) stock?
The Earnings per Share (EPS) of STEREOTAXIS INC (STXS) is expected to grow by 13.03% in the next year.